RxDoctor Payments Data

Theresa Malcom

Family · Elkhart, INNPI 1871224576

Payments from drug & device makers

$1,959in general payments, 2019–2025

Across 83 payments — averaging $23.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$350
  • GSK$342
  • Johnson & Johnson$332
  • Takeda Pharmaceuticals U.S.A., Inc.$138
  • Genentech USA, Inc.$136
  • Mylan Specialty L.p.$124
  • plus $537 from 12 others

What the payments were for

  • Food & beverage$1,91998%
  • Education$402%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,959 in reported general payments places this provider in the 75th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$25,981
Medicare patients
115
Services billed
360

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter229$168,449
Stiolto RespimatTiotropium Br/Olodaterol Hcl42$24,694
Breztri AerosphereBudesonide/Glycopyr/Formoterol37$23,649
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr36$17,193
Breo ElliptaFluticasone/Vilanterol20$14,008
Bevespi AerosphereGlycopyrrolate/Formoterol Fum11$5,356
Arnuity ElliptaFluticasone Furoate20$4,974
Albuterol Sulfate HfaAlbuterol Sulfate114$2,283
Roflumilast15$903
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$715
Montelukast Sodium46$522
Pantoprazole Sodium50$288
Doxycycline Hyclate22$197
Prednisone60$141
Azithromycin20$39

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta$342$204,625305 claims
AstraZenecaBreztri Aerosphere, Bevespi Aerosphere$350$29,00548 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,392 family providers in Indiana.

Other family in Elkhart

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →